USCB (USCB) CEO exercises stock options and sells 10,000 shares at $18.02

Rhea-AI Filing Summary

USCB Financial Holdings, Inc. insider Luis de la Aguilera, President and CEO, reported an option exercise and share sale. On January 29, 2026, he exercised 10,000 stock options at an exercise price of $7.50 per share for Class A voting common stock.

On the same date, he sold 10,000 Class A voting common shares at a weighted average price of $18.02 per share in multiple trades between $18.00 and $18.16. After these transactions, he directly owned 245,893 Class A voting common shares, including several tranches of restricted stock that vest in annual installments through future dates.

He also holds stock options on 40,000 shares at an exercise price of $11.35 per share expiring on September 23, 2029, and stock options on 160,000 shares at $12.05 per share expiring on September 27, 2031, all reported as directly owned.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DE LA AGUILERA LUIS

(Last) (First) (Middle)

C/O USCB FINANCIAL HOLDINGS, INC.

2301 N.W. 87TH AVENUE

(Street)

DORAL FL 33172

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
USCB FINANCIAL HOLDINGS, INC. [ USCB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Voting Common Stock	01/29/2026		M		10,000	A	$7.5	255,893(1)	D
Class A Voting Common Stock	01/29/2026		S		10,000	D	$18.02(2)	245,893(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.5	01/29/2026		M			10,000	04/01/2017(3)	04/01/2026	Common Stock	0	$0	0	D
Stock Option (Right to Buy)	$11.35							09/23/2020(4)	09/23/2029	Common Stock	40,000		40,000	D
Stock Option (Right to Buy)	$12.05							09/27/2022(5)	09/27/2031	Common Stock	160,000		160,000	D

Explanation of Responses:

1. Includes the grant of 27,632 shares of restricted stock which vest at a rate of one-third per year commencing on January 27, 2027, 17,082 shares of restricted stock from a grant of 25,653 shares which commenced vesting at a rate of one-third per year on January 21, 2026, 4,045 shares of restricted stock from a grant of 12,136 shares which commenced vesting at a rate of one-third per year on January 22, 2025, 7,892 shares of restricted stock from a grant of 23,678 shares which commenced vesting at a rate of one-third per year on March 8, 2024, and 41,666 shares of restricted stock from a grant of 125,000 shares which commenced vesting at a rate of one-third per year on December 31, 2024.

2. The price reported in column 4 is a weighted price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.16, inclusive. The reporting person undertakes to provide to USCB, or any security holder of USCB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The stock options vested at the rate of 25% per year commencing on April 1, 2017.

4. The stock options vested at the rate of one-third per year commencing on September 23, 2020.

5. The stock options vested at the rate of one-third per year commencing on September 27, 2022.

	/s/ Robert Anderson by P.O.A. for Luis de la Aguilera	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did USCB (USCB) report for its CEO on January 29, 2026?

USCB’s President and CEO, Luis de la Aguilera, exercised and sold shares on January 29, 2026. He exercised 10,000 stock options at $7.50 per share, then sold 10,000 Class A voting common shares at a weighted average price of $18.02 per share.

How many USCB (USCB) shares does the CEO own after the January 2026 Form 4 transactions?

After the reported transactions, the CEO directly owned 245,893 Class A voting common shares. This total includes multiple grants of restricted stock that vest over several years according to schedules beginning in 2024, 2025, 2026, and 2027.

At what prices did the USCB (USCB) CEO sell shares reported in this Form 4?

The CEO sold 10,000 Class A voting common shares at a weighted average price of $18.02 per share. The sales occurred in multiple trades at prices ranging from $18.00 to $18.16, as disclosed in the transaction footnote.

What stock options did the USCB (USCB) CEO exercise in the January 2026 filing?

He exercised 10,000 stock options with an exercise price of $7.50 per share. These options related to common stock and had originally vested at a rate of 25% per year starting on April 1, 2017, according to the vesting footnote.

What USCB (USCB) stock options does the CEO still hold after the reported transactions?

The CEO continues to hold options on 40,000 shares at $11.35 and 160,000 shares at $12.05 per share. These options expire on September 23, 2029, and September 27, 2031, respectively, and are reported as directly owned.

How are restricted stock awards described in the USCB (USCB) CEO’s Form 4 filing?

The filing notes several restricted stock grants that vest in one-third installments annually. Grants referenced include 27,632, 25,653, 12,136, 23,678, and 125,000 shares, with vesting commencement dates in 2024, 2025, 2026, and 2027 for different tranches.